Revel Pharmaceuticals Inc. — Form D
Revel Pharmaceuticals Inc. of San Francisco, CA, a company, filed a Form D exempt-offering notice with the SEC on 2020-01-23. The offering totals $1.6M, of which $533K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-01-23
- Form: D
- Accession: 0001800934-20-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $1.6M
- Amount sold: $533K
- Remaining: $1.1M
- Minimum investment: $100K
- Investors: 2
- Date of first sale: 2019-12-20
- Security types: equity
- Revenue range: No Revenues
- SEC file number: 021-358789
Issuer
- Name: Revel Pharmaceuticals Inc.
- CIK: 0001800934
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 2325 3rd Street, San Francisco, CA, 94107
- Phone: (217) 766-4292
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Aaron James Cravens | Director | San Francisco, CA |
| Aaron James Cravens | Executive Officer | San Francisco, CA |
| Patrick James Burgermeister | Director | San Francisco, CA |
| Jennifer James Cochran | Director | San Francisco, CA |
| Jennifer Cochran | Director | San Francisco, CA |
| Aaron Cravens | Executive Officer | San Francisco, CA |
Other filings by this issuer (2)
More